ABOUT ALTIS BIOSYSTEMS
Current approaches to drug development have resulted in an 88% failure rate in clinical trials and $151 billion spent every year on research and development. A key factor driving this failure rate is the use of Caco-2 cells (cancer cells) and animal testing, which are an essential part of preclinical trials and yet cannot accurately predict human results.
That’s why Altis developed a next-generation intestinal platform that produces a layer of human intestinal stem and differentiated cells – either of the large or small intestine – that can be used for compound screening, disease modeling, and microbiome research. It can also be used to study many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
Altis Biosystems is a spin-out company from the University of North Carolina at Chapel Hill and based in Durham, North Carolina. The intellectual property behind its stem cell platform was created as part of an NIH Transformative Research Award to develop a microfluidic organ-on-a-chip mimic of the human colon and awarded to Altis’ scientific founders. We are proud to have industry leading scientists on our team, capable of disrupting preclinical studies, and accelerating drug development to produce more effective drugs.
FEATURED PRODUCTS
The monolayer format produces a continuous layer of stem or differentiated cells on a flat and porous surface.
The form factor for RepliGut® kit is a multiwell plate, which can be provided in 12 or 96 well sizes, depending on a scientist's needs. Each well contains a cassette insert with an individual tissue sample.
Accurate biological screening based on real human intestinal tissue, with a standardized workflow for reliable and reproducible data, RepliGut® represents the next generation for in vitro testing with faster actionable data.
CONTACT INFORMATION
Altis Biosystems
6 Davis Drive, Suite 500
Durham, NC 27709
UNITED STATES
Contact: Niki Heinz
FEATURED ARTICLES
-
![intestine iStock-1138681666]( "A Human HTS Platform For Assessing Gastrointestinal Toxicity (GIT) Risk In Early Development")
We review a solution for the need for human models of GI risk assessment that can be utilized for drug optimization in early development.
-
![gastro intestine digestion stomach iStock-1265549997]( "TNF-a Is Critical To The Pathogenesis Of Inflammatory Bowel Diseases")
A model of human IBD has been established to enable the screening and detailed characterization of novel therapeutic agents combining measures that bridge non-invasive and high-throughput testing with clinically relevant endpoints of this disease.
-
![Cell and Gene genetic lab iStock-1209892070]( "Unpacking The Complexity Of In Vitro Intestinal Models")
Read how technological advances are enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials.
-
![stem cell research female_450x300]( "Evaluating Microbiome Therapies With Intestinal Cell Models")
Advanced models of the gut leveraging intestinal and colonic stem cells are enabling the development of robust systems for evaluating the changes in the microbiome and screening potential drug candidates.
-
The ability to grow and expand primary human epithelial cells in vitro has been a significant advancement in the field of gastrointestinal biology.
-
![Cell]( "Increasing The Efficiency Of Drug Development With Preclinical Testing Using Human Intestinal Stem Cells")
More efficient development of drugs with attractive side effect profiles requires robust, easy-to-use, cost-effective in vitro gut models that are physiologically representative of the human intestinal tract.
-
![CRISPR Gene Editing]( "Enhancing Human Gut Tissue Models Through Gene Editing")
The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for preclinical models, but obtaining these tissues is challenging.
-
![Intestine iStock-1294898140]( "Recapitulating The Inflammatory Environment Of The Intestine In Vitro")
Intestinal inflammatory diseases are highly complex, which has thus far prevented development of an effective in vitro disease model.
-
![intestine iStock-1138681666]( "Accurately Recapitulate Environmental Niches In Intestinal In Vitro Models")
Advanced microphysiological systems can replicate aspects of intestinal complexity. Availability of such models is key to progress in compound screening, disease modeling, and microbiome research.
-
![gastro intestine digestion stomach iStock-1265549997]( "Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity")
This article reviews an in vitro human intestinal model that is helping to develop a system that could help pharma companies identify GI toxicity issues early in the drug development process.
WEBINARS
-
![Altis Webinar]( "Studying The Responses To Cytokines Using Novel In Vitro Stem Cell Platforms")
This webinar discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.
VIDEOS
-
![Altis]( "Microphysiological Systems: The Future Of Healthcare")
We discuss the future of healthcare, and what's the next big thing in pharma. Hear how the development of microphysiological systems will support the development of drugs from discovery to humans.
-
![Altis]( "A Gut Feeling About The Future Of Healthcare")
Scott Magness, Chief Scientific Advisor at Altis Biosystems, discusses the impact that RepliGut®- a human stem cell-derived platform that recreates the intestinal epithelium - may have on stem cell research and drug testing.
NEWS
- Altis Biosystems Awards New Research Funding To Armed Forces Radiobiology Research Institute
- Altis Biosystems Appoints Jimmy Smedley, Ph.D. Chief Operating Officer
- Altis Biosystems Announces New Research Funding Initiative
- Altis Biosystems Appoints Bill Thelin, Ph.D. Chief Scientific Officer
- Altis Biosystems Announces Completion Of A $3.1 Million Seed Investment Led By VentureSouth